🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis

RecruitingPhase 2Ages 18 Years - 70 YearsAllTanta University
NCT07745426 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) \>2.6. * Both sexes. * Age ranges between 18 and 70 years old. * Patients receiving conventional DMARDs Exclusion Criteria: * Pregnant and lactating females. * Patients receiving biological DMARDs or targeted synthetic DMARDs. * Patients with renal and hepatic dysfunction. * Patients with other inflammatory/autoimmune diseases, active infection, or malignancies. * Patients with bleeding disorders, receiving warfarin or other anticoagulants. * Patients receiving antioxidants. * Patients with hypersensitivity to study medications.
💊

What it tests

  • Diosmin
  • Rebamipide 100mg
  • Convential medical treatment
📍

Where

1 site
Faculty of Pharmacy Tanta University
Tanta, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy